MannKind Corporation (NASDAQ:MNKD) announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted, MannKind's resubmission of its New Drug Application (NDA) for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of December 29, 2010.
It is said this insulin peaks at 14 to 14 minutes. That is interesting.
As a side note, I find it faster to read Scott S's Tweets than my news reader for news like this. Thanks Scott.